WuXi Biologics (Cayman)WXIBF 97 ROC (Joel Greenblatt) % is 22.70% as of Dec. 2025, which is 5% above its 10-year median of 21.70. GuruFocus rates WXIBF with a GF Score™ of 97/100 and a GF Value™ of $5.14 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 1,323 Biotechnology companies, WuXi Biologics (Cayman) ranks better than 87.68% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. WuXi Biologics (Cayman)'s annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 22.70%.
The historical rank and industry rank for WuXi Biologics (Cayman)'s ROC (Joel Greenblatt) % or its related term are showing as below:
WXIBF'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 14.5 Med: 21.7 Max: 29.78
Current: 21.15
During the past 12 years, WuXi Biologics (Cayman)'s highest ROC (Joel Greenblatt) % was 29.78%. The lowest was 14.50%. And the median was 21.70%.
WXIBF's ROC (Joel Greenblatt) % is ranked better than 87.68% of 1323
companies
in the Biotechnology industry
Industry Median: -296.6
vs WXIBF: 21.15
WuXi Biologics (Cayman)'s 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -3.10% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
WuXi Biologics (Cayman) ROC (Joel Greenblatt) % Related Terms
WuXi Biologics (Cayman) ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for WuXi Biologics (Cayman)'s ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WXIBF vs VRTX, REGN, ALNY: ROC (Joel Greenblatt) % Comparison
For the Biotechnology subindustry, WuXi Biologics (Cayman)'s ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WuXi Biologics (Cayman) ROC (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, WuXi Biologics (Cayman)'s ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where WuXi Biologics (Cayman)'s ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 22.70% mean?
WuXi Biologics (Cayman) (WXIBF) has a ROC (Joel Greenblatt) % of 22.70% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on WuXi Biologics (Cayman) and its competitors. This is near median its historical median of 21.70. Over the past decade, WuXi Biologics (Cayman)'s ROC (Joel Greenblatt) % has ranged from 14.50 to 29.78. According to the industry distribution chart, WuXi Biologics (Cayman) ranks #163 out of 1323 companies in the Biotechnology industry, placing it in the top 12.3%.
Is WuXi Biologics (Cayman)'s ROC (Joel Greenblatt) % too high?
WuXi Biologics (Cayman)'s current ROC (Joel Greenblatt) % of 22.70% is near median its 10-year median of 21.70. Over the past 10 years, this metric has ranged from a low of 14.50 to a high of 29.78. Based on the distribution chart, WuXi Biologics (Cayman) ranks #163 out of 1323 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, WuXi Biologics (Cayman) has a GF Score™ of 97/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does WuXi Biologics (Cayman)'s ROC (Joel Greenblatt) % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, WuXi Biologics (Cayman) ranks #163 out of 1323 companies for ROC (Joel Greenblatt) %. This places WuXi Biologics (Cayman) in the top 12% of its industry — outperforming the majority of peers. Historically, WuXi Biologics (Cayman)'s own ROC (Joel Greenblatt) % has ranged from 14.50 to 29.78 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on WuXi Biologics (Cayman) and its competitors. WuXi Biologics (Cayman)'s current ROC (Joel Greenblatt) % is 22.70%, which is near median its own 10-year median of 21.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi Biologics (Cayman) stock overvalued right now?
Based on GuruFocus' analysis, WuXi Biologics (Cayman) (WXIBF) is currently considered Modestly Undervalued. The stock's GF Value™ is $5.14, compared to a current price of $4.60 — trading 10.5% below its estimated fair value. The current ROC (Joel Greenblatt) % is 22.70%, which is near median its 10-year median of 21.70. WuXi Biologics (Cayman)'s overall GF Score™ is 97/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For WuXi Biologics (Cayman) (WXIBF), the current ROC (Joel Greenblatt) % is 22.70% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is WuXi Biologics (Cayman) (WXIBF) Overvalued in 2026?
Based on GuruFocus' analysis, WuXi Biologics (Cayman) stock appears to be undervalued.
The current stock price of $4.60 is trading 10.5% below its estimated GF Value™ of $5.14.
GuruFocus considers WuXi Biologics (Cayman) to be Modestly Undervalued.
Key valuation signals for WXIBF:
ROC (Joel Greenblatt) %: 22.70% (near median its 10-year median of 21.70)
GF Value™: $5.14 vs. price of $4.60 (10.5% below fair value)
No single metric tells the full story. See the WXIBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
WuXi Biologics is one of the largest biologics contract development and manufacturing organizations in the world. Incorporated in 2014 following the reorganization of WuXi PharmaTech, WuXi engages in full-lifecycle services beginning from drug discovery, clinical trials, and commercial manufacturing. It focuses on developing refining and manufacturing processes to increase scalability and efficiency for pharmaceutical companies looking to outsource and access specialized knowledge. As of 2024, WuXi derives more than 60% of its revenue from US companies and focuses its operations on high-growth, late-stage, and commercial projects in the biologics sector. WuXi competes with Samsung Biologics, Lonza, and Fujifilm for contracts.
97GF Score
Get the complete analysis for WXIBF
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WXIBF has been successfully added to your 
